BIMERVAX 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IB/0011/G 
This was an application for a group of variations. 
20/12/2023 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
A.3 - Administrative change - Change in name of the 
AS or of an excipient 
II/0005/G 
This was an application for a group of variations. 
23/11/2023 
n/a 
B.I.b.1.f - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Change outside the 
approved specifications limits range for the AS 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
II/0002 
Submission of the final study report HIPRA-HH-1 
09/11/2023 
n/a 
Not applicable 
listed as a category 3 study in the RMP. This is a 
phase I/IIa study to evaluate safety and 
immunogenicity of PHH-1V against SARS-COV-2 in 
adult healthy volunteers. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
II/0008 
Submission of the final report from study HIPRA-HH-
12/10/2023 
n/a 
10 listed as a category 3 study in the RMP. This is a 
phase 2b, double-blind, randomised, active-
controlled, multi-centre, non-inferiority trial to assess 
immunogenicity and safety of a booster vaccination 
with a recombinant protein RBD fusion dimer 
candidate (PHH-1V) against SARS-CoV-2, in adults 
fully vaccinated with adenovirus vaccine against 
For more information, please refer to the Summary of 
Product Characteristics. 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COVID-19. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IB/0003 
C.I.11.z - Introduction of, or change(s) to, the 
18/08/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0001 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
29/06/2023 
SmPC and PL 
To extend the shelf-life of the biological finished product, in 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
accordance with the approved stability protocol, from 1 
year to 15 months when stored at 2 ºC – 8 ºC. 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
